JP7651557B2 - Ｉｉｉ型受容体チロシンキナーゼ阻害剤としてのヘテロ環式ピラゾール誘導体 - Google Patents
Ｉｉｉ型受容体チロシンキナーゼ阻害剤としてのヘテロ環式ピラゾール誘導体 Download PDFInfo
- Publication number
- JP7651557B2 JP7651557B2 JP2022511322A JP2022511322A JP7651557B2 JP 7651557 B2 JP7651557 B2 JP 7651557B2 JP 2022511322 A JP2022511322 A JP 2022511322A JP 2022511322 A JP2022511322 A JP 2022511322A JP 7651557 B2 JP7651557 B2 JP 7651557B2
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- cyclopenta
- dihydrothieno
- indazol
- pyrazol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962891097P | 2019-08-23 | 2019-08-23 | |
| US62/891,097 | 2019-08-23 | ||
| PCT/US2020/047552 WO2021041276A1 (en) | 2019-08-23 | 2020-08-22 | Heterocyclic pyrazole derivatives as type iii receptor tyrosine kinase inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022545019A JP2022545019A (ja) | 2022-10-24 |
| JP2022545019A5 JP2022545019A5 (https=) | 2023-08-18 |
| JP7651557B2 true JP7651557B2 (ja) | 2025-03-26 |
Family
ID=74685735
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022511322A Active JP7651557B2 (ja) | 2019-08-23 | 2020-08-22 | Ｉｉｉ型受容体チロシンキナーゼ阻害剤としてのヘテロ環式ピラゾール誘導体 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12448394B2 (https=) |
| EP (1) | EP4017853A4 (https=) |
| JP (1) | JP7651557B2 (https=) |
| KR (1) | KR20220051365A (https=) |
| CN (1) | CN114502553B (https=) |
| AU (1) | AU2020337883B2 (https=) |
| BR (1) | BR112022003383A2 (https=) |
| CA (1) | CA3151821A1 (https=) |
| MX (1) | MX2022002062A (https=) |
| TW (1) | TWI759829B (https=) |
| WO (1) | WO2021041276A1 (https=) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006502097A (ja) | 2002-05-15 | 2006-01-19 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Ｐｄｇｆ受容体阻害剤としてのｎ−置換三環状３−アミノピラゾール |
| JP2008528468A (ja) | 2005-01-21 | 2008-07-31 | アステックス・セラピューティクス・リミテッド | 医薬化合物 |
| JP2009513615A (ja) | 2005-10-28 | 2009-04-02 | アストラゼネカ アクチボラグ | 癌の治療においてチロシンキナーゼ阻害剤として使用するための４−（３−アミノピラゾール）ピリミジン誘導体 |
| JP2013528580A (ja) | 2010-04-30 | 2013-07-11 | アステックス、セラピューティックス、リミテッド | ピラゾリルキナゾリンキナーゼ阻害剤 |
| US20130274255A1 (en) | 2012-04-12 | 2013-10-17 | Development Center For Biotechnology | Heterocyclic pyrazole compounds, method for preparing the same and use thereof |
| JP2015511638A (ja) | 2012-03-30 | 2015-04-20 | エージェンシー フォー サイエンス，テクノロジー アンド リサーチ | Ｍｎｋ１およびｍｎｋ２調節剤としての二環式ヘテロアリール誘導体、およびその使用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2425677C2 (ru) | 2005-01-21 | 2011-08-10 | Астекс Терапьютикс Лимитед | Соединения, предназначенные для использования в фармацевтике |
| JP2010505859A (ja) | 2006-10-06 | 2010-02-25 | アイアールエム・リミテッド・ライアビリティ・カンパニー | タンパク質キナーゼ阻害剤およびそれを使用するための方法 |
| KR101122481B1 (ko) | 2007-05-04 | 2012-02-29 | 아이알엠 엘엘씨 | Ｃ-ｋｉｔ 및 ｐｄｇｆｒ 키나제 억제제로서의 피리미딘 유도체 및 조성물 |
| EA024729B1 (ru) * | 2009-11-13 | 2016-10-31 | Джиноско | Киназные ингибиторы |
| UA112425C2 (uk) | 2010-12-13 | 2016-09-12 | Еррей Біофарма Інк. | ЗАМІЩЕНІ N-(1H-ІНДАЗОЛ-4-ІЛ)ІМІДАЗО[1,2-a]ПІРИДИН-3-КАРБОКСАМІДНІ СПОЛУКИ ЯК ІНГІБІТОРИ РЕЦЕПТОРНОЇ ТИРОЗИНКІНАЗИ ІІІ ТИПУ |
| US8877763B2 (en) * | 2012-03-22 | 2014-11-04 | Genosco | Substituted pyridopyrimidine compounds and their use as FLT3 inhibitors |
| MX2018006856A (es) | 2015-12-07 | 2018-08-01 | Plexxikon Inc | Compuestos y metodos para modulacion de la quinasa, e indicaciones de los mismos. |
-
2020
- 2020-08-21 TW TW109128678A patent/TWI759829B/zh active
- 2020-08-22 BR BR112022003383A patent/BR112022003383A2/pt unknown
- 2020-08-22 CN CN202080059010.6A patent/CN114502553B/zh active Active
- 2020-08-22 MX MX2022002062A patent/MX2022002062A/es unknown
- 2020-08-22 EP EP20856905.3A patent/EP4017853A4/en active Pending
- 2020-08-22 KR KR1020227009059A patent/KR20220051365A/ko active Pending
- 2020-08-22 AU AU2020337883A patent/AU2020337883B2/en active Active
- 2020-08-22 WO PCT/US2020/047552 patent/WO2021041276A1/en not_active Ceased
- 2020-08-22 JP JP2022511322A patent/JP7651557B2/ja active Active
- 2020-08-22 US US17/636,116 patent/US12448394B2/en active Active
- 2020-08-22 CA CA3151821A patent/CA3151821A1/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006502097A (ja) | 2002-05-15 | 2006-01-19 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Ｐｄｇｆ受容体阻害剤としてのｎ−置換三環状３−アミノピラゾール |
| JP2008528468A (ja) | 2005-01-21 | 2008-07-31 | アステックス・セラピューティクス・リミテッド | 医薬化合物 |
| JP2009513615A (ja) | 2005-10-28 | 2009-04-02 | アストラゼネカ アクチボラグ | 癌の治療においてチロシンキナーゼ阻害剤として使用するための４−（３−アミノピラゾール）ピリミジン誘導体 |
| JP2013528580A (ja) | 2010-04-30 | 2013-07-11 | アステックス、セラピューティックス、リミテッド | ピラゾリルキナゾリンキナーゼ阻害剤 |
| JP2015511638A (ja) | 2012-03-30 | 2015-04-20 | エージェンシー フォー サイエンス，テクノロジー アンド リサーチ | Ｍｎｋ１およびｍｎｋ２調節剤としての二環式ヘテロアリール誘導体、およびその使用 |
| US20130274255A1 (en) | 2012-04-12 | 2013-10-17 | Development Center For Biotechnology | Heterocyclic pyrazole compounds, method for preparing the same and use thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022545019A (ja) | 2022-10-24 |
| WO2021041276A1 (en) | 2021-03-04 |
| US12448394B2 (en) | 2025-10-21 |
| US20220289759A1 (en) | 2022-09-15 |
| CA3151821A1 (en) | 2021-03-04 |
| AU2020337883B2 (en) | 2025-08-28 |
| EP4017853A4 (en) | 2023-08-30 |
| BR112022003383A2 (pt) | 2022-05-17 |
| CN114502553B (zh) | 2024-07-26 |
| CN114502553A (zh) | 2022-05-13 |
| TW202115087A (zh) | 2021-04-16 |
| TWI759829B (zh) | 2022-04-01 |
| AU2020337883A1 (en) | 2022-03-24 |
| EP4017853A1 (en) | 2022-06-29 |
| KR20220051365A (ko) | 2022-04-26 |
| MX2022002062A (es) | 2022-04-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7189956B2 (ja) | Ｓｏｓ１阻害剤としての新規なベンジルアミノ置換ピリドピリミジノンおよび誘導体 | |
| JP5871896B2 (ja) | Ｂ−ｒａｆキナーゼインヒビター | |
| CN114375202A (zh) | 抗癌组合疗法 | |
| JP2020504742A (ja) | 新規のベンジルアミノ置換キナゾリンおよびｓｏｓ１阻害剤としての誘導体 | |
| JP2020503374A (ja) | Ｂｃｌ６阻害剤としての新規の６−アミノキノリノン化合物および誘導体 | |
| JP7206188B2 (ja) | Ｉｉｉ型受容体チロシンキナーゼ阻害剤としてのキノキサリン化合物 | |
| KR20150027121A (ko) | 신규 화합물 | |
| JP2021514373A (ja) | Ｅｇｆｒ阻害剤としての新たなベンズイミダゾール化合物および誘導体 | |
| JP2020519588A (ja) | 腫瘍を治療するための薬剤の製造におけるｂｔｋ阻害剤との組み合わせでのｅｚｈ２阻害剤の使用 | |
| JP7651557B2 (ja) | Ｉｉｉ型受容体チロシンキナーゼ阻害剤としてのヘテロ環式ピラゾール誘導体 | |
| RU2833004C2 (ru) | Производные гетероциклического пиразола как ингибиторы рецепторной тирозикиназы типа III | |
| WO2023008577A1 (ja) | Ｒａｓ／Ｒａｆ結合阻害化合物 | |
| HK40012508A (en) | Quinoxaline compounds as type iii receptor tyrosine kinase inhibitors | |
| HK40012508B (en) | Quinoxaline compounds as type iii receptor tyrosine kinase inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20220329 |
|
| RD01 | Notification of change of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7426 Effective date: 20220329 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230809 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20230809 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240730 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20240731 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20241030 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20241227 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250124 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20250218 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20250313 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7651557 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |